BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 14724049)

  • 1. Voluntary exercise augments acute effects of CB1-receptor inverse agonist on body weight loss in obese and lean mice.
    Zhou D; Shearman LP
    Pharmacol Biochem Behav; 2004 Jan; 77(1):117-25. PubMed ID: 14724049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice.
    Irwin N; Hunter K; Frizzell N; Flatt PR
    Eur J Pharmacol; 2008 Feb; 581(1-2):226-33. PubMed ID: 18191122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabinoid-1 receptor inhibition prevents the reduction of 24-hour energy expenditure with weight loss.
    Strack AM; Nicolich S; Faidley T; Achanfuo-Yeboah J; Cunningham PK; Hora D; Thompson D; Hickey G; Johnson-Levonas AO; Fong TM; Heymsfield SB
    Metabolism; 2012 Apr; 61(4):546-53. PubMed ID: 22001334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice.
    Chen RZ; Huang RR; Shen CP; MacNeil DJ; Fong TM
    Brain Res; 2004 Mar; 999(2):227-30. PubMed ID: 14759503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice.
    Shearman LP; Rosko KM; Fleischer R; Wang J; Xu S; Tong XS; Rocha BA
    Behav Pharmacol; 2003 Dec; 14(8):573-82. PubMed ID: 14665974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats.
    Merroun I; Sánchez-González C; Martínez R; López-Chaves C; Porres JM; Aranda P; Llopis J; Galisteo M; Zarzuelo A; Errami M; López-Jurado M
    Metabolism; 2013 Nov; 62(11):1641-50. PubMed ID: 23932644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity.
    Wang Q; Perrard XD; Perrard JL; Mansoori A; Smith CW; Ballantyne CM; Wu H
    Obesity (Silver Spring); 2011 Mar; 19(3):505-13. PubMed ID: 20885384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the CB1 cannabinoid receptor inverse agonist AM251 on food intake and body weight in mice lacking mu-opioid receptors.
    Chen RZ; Frassetto A; Fong TM
    Brain Res; 2006 Sep; 1108(1):176-8. PubMed ID: 16828068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM 251 in rats: indirect behavioural mediation.
    Tallett AJ; Blundell JE; Rodgers JR
    Behav Pharmacol; 2007 Nov; 18(7):591-600. PubMed ID: 17912043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of independent and combined chronic metabolic effects of GIP and CB1 receptor blockade in high-fat fed mice.
    Irwin N; Hunter K; Flatt PR
    Peptides; 2008 Jun; 29(6):1036-41. PubMed ID: 18291559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of a palatable dietary option is not preferentially reduced by cannabinoid CB1 receptor antagonist AM251 in female C57Bl/6J mice.
    Mathes CM; Ferrara M; Rowland NE
    Pharmacol Biochem Behav; 2009 Nov; 94(1):119-23. PubMed ID: 19660493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity.
    Ravinet Trillou C; Delgorge C; Menet C; Arnone M; Soubrié P
    Int J Obes Relat Metab Disord; 2004 Apr; 28(4):640-8. PubMed ID: 14770190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice.
    Avraham Y; Menachem AB; Okun A; Zlotarav O; Abel N; Mechoulam R; Berry EM
    Brain Res Bull; 2005 Mar; 65(2):117-23. PubMed ID: 15763177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity.
    Meye FJ; Trezza V; Vanderschuren LJ; Ramakers GM; Adan RA
    Mol Psychiatry; 2013 Dec; 18(12):1294-301. PubMed ID: 23070073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voluntary exercise and sucrose consumption enhance cannabinoid CB1 receptor sensitivity in the striatum.
    De Chiara V; Errico F; Musella A; Rossi S; Mataluni G; Sacchetti L; Siracusano A; Castelli M; Cavasinni F; Bernardi G; Usiello A; Centonze D
    Neuropsychopharmacology; 2010 Jan; 35(2):374-87. PubMed ID: 19776732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuation of food intake in chicks by an inverse agonist of cannabinoid receptor 1 administered by either injection or ingestion in hydrocolloid carriers.
    Novoseletsky N; Nussinovitch A; Friedman-Einat M
    Gen Comp Endocrinol; 2011 Feb; 170(3):522-7. PubMed ID: 21094647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice.
    Verty AN; Lockie SH; Stefanidis A; Oldfield BJ
    Int J Obes (Lond); 2013 Feb; 37(2):279-87. PubMed ID: 22473329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responses to the cannabinoid receptor-1 antagonist, AM251, are more robust with age and with high-fat feeding.
    Judge MK; Zhang Y; Scarpace PJ
    J Endocrinol; 2009 Nov; 203(2):281-90. PubMed ID: 19679649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats.
    Vickers SP; Webster LJ; Wyatt A; Dourish CT; Kennett GA
    Psychopharmacology (Berl); 2003 Apr; 167(1):103-11. PubMed ID: 12632249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
    Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.